Key Points
- Pharvaris director Robert Glassman sold 8,667 shares at an average price of $38.27, worth approximately $331,686. Following the transaction, his direct holdings fell 45.22% to 10,500 shares.
- Glassman also sold 8,000 shares on September 9 for $300,400, indicating more than $632,000 in insider sales within a week.
- Despite the insider selling, analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $59.87 versus the stock’s recent price near $38. Pharvaris recently reported an adjusted quarterly loss of $0.81 per share, missing estimates.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Robert Glassman sold 8,667 shares of the firm's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $38.27, for a total value of $331,686.09. Following the completion of the transaction, the director directly owned 10,500 shares in the company, valued at $401,835. This trade represents a 45.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Robert Glassman also recently made the following trade(s):
- On Wednesday, September 9th, Robert Glassman sold 8,000 shares of Pharvaris stock. The stock was sold at an average price of $37.55, for a total value of $300,400.00.
Pharvaris Price Performance
Shares of NASDAQ PHVS opened at $38.00 on Friday. Pharvaris N.V. has a 1-year low of $20.65 and a 1-year high of $43.25. The company has a market capitalization of $2.49 billion, a price-to-earnings ratio of -12.46 and a beta of -2.33. The business has a 50-day moving average of $35.35 and a 200-day moving average of $31.69.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Research analysts expect that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.
Institutional Investors Weigh In On Pharvaris
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP bought a new stake in shares of Pharvaris in the 2nd quarter worth approximately $41,000. CoreCap Advisors LLC acquired a new stake in Pharvaris in the second quarter worth $93,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in Pharvaris in the fourth quarter worth $139,000. Public Employees Retirement System of Ohio bought a new stake in Pharvaris in the second quarter valued at $196,000. Finally, Algert Global LLC bought a new position in shares of Pharvaris during the second quarter worth about $238,000.
Wall Street Analyst Weigh In
A number of research firms have recently commented on PHVS. Citizens Jmp boosted their target price on shares of Pharvaris from $75.00 to $79.00 and gave the stock a "market outperform" rating in a research report on Wednesday, September 9th. Rosenblatt Securities set a $60.00 price target on shares of Pharvaris in a research note on Wednesday, September 9th. Royal Bank Of Canada upped their price objective on shares of Pharvaris from $52.00 to $62.00 and gave the company an "outperform" rating in a research report on Wednesday, September 9th. Cantor Fitzgerald restated an "overweight" rating and set a $65.00 target price on shares of Pharvaris in a research note on Monday. Finally, Leerink Partners raised their target price on Pharvaris from $50.00 to $65.00 and gave the company an "outperform" rating in a research note on Wednesday, September 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $59.87.
Get Our Latest Analysis on Pharvaris
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.
Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
